RNA Formulation Videos

  1. Q&A On LNP Cell-Specific Delivery 11/28/2022

    In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery for Strand Therapeutics, outline several examples of foundational research that could provide insights into how we attain more specific cellular uptake of LNPs.

  2. mRNA's Future Beyond The COVID Vaccines 11/28/2022

    In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, unpack which learnings can be adapted from ASO-LNPs to mRNA/LNPs and from mRNA vaccines to mRNA therapeutics. They also touch upon which learnings cannot be neatly carried over from these previous success stories.

  3. mRNA LNP Scale Up For GMP Vaccine Production 4/14/2022

    Explore an overview of the development and scale-up activities needed to develop high quality lipid nanoparticles and progress this saRNA vaccine to the clinic.

  4. Molecular And Colloidal Ionization Properties Of Lipid Nanoparticle mRNA Vaccines 4/13/2022

    Dr. Michael Buschmann, George Mason University, presents an overview of molecular and colloidal ionization properties of lipid nanoparticle mRNA vaccines.

  5. Scale-Up And Production Of Key Lipids Used In mRNA Delivery Systems 2/13/2025

    Discover key strategies for overcoming challenges in the industrial-scale production of ionizable and PEG lipids to optimize mRNA vaccine formulation and address critical manufacturing requirements.

  6. RNA-LNP Manufacturing Technology Delivering Transformative Medicines 10/13/2022

    NxGen™ microfluidic technology enables controlled and precise assembly of high-quality, uniform LNPs, ensuring reproducible scale-up of RNA-LNPs while maximizing drug loading and particle quality.

  7. Insights And Strategies For GMP Manufacturing Of RNA-Lipid Nanoparticles 4/25/2024

    The emergence of RNA-encapsulated-lipid nanoparticles has introduced a seismic shift in biopharma innovation. But how will the industry adapt to diversifying applications and scales going forward?

  8. R&D & CMC Priorities For LNPs Beyond Cell-Specific Delivery 12/4/2024

    It goes without saying that achieving cell-specific delivery is the most often discussed challenge facing the RNA-LNP field near- and long-term. However, as these three LNP experts share in this Advancing RNA Live clip, they have a whole list of additional R&D and CMC priorities we must address/accomplish to improve RNA-LNPs’ efficacy in personalized and gene therapy approaches.

  9. How To Manufacture LNPs On The Nova Benchtop System 4/18/2024

    Walk step-by-step instructions through how you can set up the Nova Benchtop System and make your first LNPs.

  10. CMC Innovations Worth Watching In The RNA-LNP Space 12/4/2024

    Sanofi’s Sumit Luthra shares several of the analytical and manufacturing innovations/improvements he’s watching and waiting for that will improve our knowledge of LNP composition, structure, function, and quality.